Literature DB >> 21750651

Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2.

Dipankar Ray1, Aarif Ahsan, Abigail Helman, Guoan Chen, Ashok Hegde, Susmita Ramanand Gurjar, Lili Zhao, Hiroaki Kiyokawa, David G Beer, Theodore S Lawrence, Mukesh K Nyati.   

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in a variety of epithelial tumors and is considered to be an important therapeutic target. Although gene amplification is responsible for EGFR overexpression in certain human malignancies including lung and head and neck cancers, additional molecular mechanisms are likely. Here, we report a novel interaction of EGFR with an HECT-type ubiquitin ligase SMURF2, which can ubiquitinate, but stabilize EGFR by protecting it from c-Cbl-mediated degradation. Conversely, small interfering RNA (siRNA)-mediated knockdown of SMURF2 destabilized EGFR, induced an autophagic response and reduced the clonogenic survival of EGFR-expressing cancer cell lines, with minimal effects on EGFR-negative cancer cells, normal fibroblasts, and normal epithelial cells. UMSCC74B head and neck squamous cancer cells, which form aggressive tumors in nude mice, significantly lost in vivo tumor-forming ability on siRNA-mediated SMURF2 knockdown. Gene expression microarray data from 443 lung adenocarcinoma patients, and tissue microarray data from 67 such patients, showed a strong correlation of expression between EGFR and SMURF2 at the messenger RNA and protein levels, respectively. Our findings suggest that SMURF2-mediated protective ubiquitination of EGFR may be responsible for EGFR overexpression in certain tumors and support targeting SMURF2-EGFR interaction as a novel therapeutic approach in treating EGFR-addicted tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750651      PMCID: PMC3132843          DOI: 10.1593/neo.11632

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  47 in total

1.  Dual mode of degradation of Cdc25 A phosphatase.

Authors:  Maddalena Donzelli; Massimo Squatrito; Dvora Ganoth; Avram Hershko; Michele Pagano; Giulio F Draetta
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

2.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.

Authors:  Patrick Y Chun; Felix Y Feng; Ashley M Scheurer; Mary A Davis; Theodore S Lawrence; Mukesh K Nyati
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

4.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover.

Authors:  Gianni M Di Guglielmo; Christine Le Roy; Anne F Goodfellow; Jeffrey L Wrana
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

5.  Survival of cancer cells is maintained by EGFR independent of its kinase activity.

Authors:  Zhang Weihua; Rachel Tsan; Wei-Chien Huang; Qiuyu Wu; Chao-Hua Chiu; Isaiah J Fidler; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

6.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

7.  Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery.

Authors:  Herve Barriere; Csilla Nemes; Kai Du; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

Review 8.  Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis.

Authors:  Luca Busino; Massimo Chiesa; Giulio F Draetta; Maddalena Donzelli
Journal:  Oncogene       Date:  2004-03-15       Impact factor: 9.867

9.  Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage.

Authors:  Luca Busino; Maddalena Donzelli; Massimo Chiesa; Daniele Guardavaccaro; Dvora Ganoth; N Valerio Dorrello; Avram Hershko; Michele Pagano; Giulio F Draetta
Journal:  Nature       Date:  2003-11-06       Impact factor: 49.962

10.  The HECT E3 ligase Smurf2 is required for Mad2-dependent spindle assembly checkpoint.

Authors:  Evan C Osmundson; Dipankar Ray; Finola E Moore; Qingshen Gao; Gerald H Thomsen; Hiroaki Kiyokawa
Journal:  J Cell Biol       Date:  2008-10-13       Impact factor: 10.539

View more
  26 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 3.  SMURF and NEDD4: sharp shooters monitor the gate keepers and ion traffic controllers of lead astray cell.

Authors:  Ammad Ahmad Farooqi; Makhdoom Saad Waseem; Asma M Riaz; Shahzad Bhatti
Journal:  J Membr Biol       Date:  2011-09-15       Impact factor: 1.843

4.  Prediction of novel genes associated with negative regulators of toll-like receptors-induced inflammation based on endotoxin tolerance.

Authors:  Yan Yang; Hanxiao Sun; Xuemei Mo; Yi Liu; Hongwei Jia; Xiuying Li; Guang Zhang; Qin Li
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

Review 5.  Endocytosis of receptor tyrosine kinases.

Authors:  Lai Kuan Goh; Alexander Sorkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

6.  Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.

Authors:  Paramita Ray; Krishnan Raghunathan; Aarif Ahsan; Uday Sankar Allam; Shirish Shukla; Venkatesha Basrur; Sarah Veatch; Theodore S Lawrence; Mukesh K Nyati; Dipankar Ray
Journal:  J Biol Chem       Date:  2020-07-15       Impact factor: 5.157

7.  Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Authors:  Laura Conradt; Klaus Godl; Christoph Schaab; Andreas Tebbe; Stefan Eser; Sandra Diersch; Christoph W Michalski; Jörg Kleeff; Angelika Schnieke; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

8.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

9.  Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.

Authors:  Dipankar Ray; Paramita Ray; Daysha Ferrer-Torres; Zhuwen Wang; Derek Nancarrow; Hee-Won Yoon; May San Martinho; Tonaye Hinton; Scott Owens; Dafydd Thomas; Hui Jiang; Theodore S Lawrence; Jules Lin; Kiran Lagisetty; Andrew C Chang; David G Beer
Journal:  Gastroenterology       Date:  2019-11-09       Impact factor: 22.682

10.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.